Building in efficacy: developing solutions to combat drug‐resistant S. pneumoniae
Author:
Open Access
- 1 January 2004
- journal article
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 10 (s2) , 18-27
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adultsJournal of Antimicrobial Chemotherapy, 2003
- A review of the antimicrobial activity of clavulanateJournal of Antimicrobial Chemotherapy, 2003
- Effects of an Efflux Mechanism and Ribosomal Mutations on Macrolide Susceptibility of Haemophilus influenzae Clinical IsolatesAntimicrobial Agents and Chemotherapy, 2003
- Efficacies of ABT-773, a New Ketolide, against Experimental Bacterial InfectionsAntimicrobial Agents and Chemotherapy, 2001
- The Emergence ofStreptococcus pneumoniaeResistant to Macrolide Antimicrobial Agents: A 6‐Year Population‐Based AssessmentThe Journal of Infectious Diseases, 2000
- Bacteriologic Response to Oral Cephalosporins: Are Established Susceptibility Breakpoints Appropriate in the Case of Acute Otitis Media?The Journal of Infectious Diseases, 1997
- Pharmacokinetics and pharmacodynamics of antibiotics in otitis media*The Pediatric Infectious Disease Journal, 1996
- Antimicrobial resistance issues of the futureDiagnostic Microbiology and Infectious Disease, 1996
- Measuring the comparative efficacy of antibacterial agents for acute otitis media: The “Pollyanna phenomenon”The Journal of Pediatrics, 1992
- TREATMENT OF PNEUMONIA WITH 2-(p-AMINOBENZENESULPHONAMIDO) PYRIDINEThe Lancet, 1938